Moderna’s COVID-19 vaccine was shown to be effective in adolescents aged 12-17 and showed no new or major safety problems in a clinical trial, the developer said on Tuesday.The development potentially sets the stage for a second vaccine for school-aged children to be authorized in the summertime.Moderna Inc, whose vaccine is authorized for adults 18 and older, said it will submit the findings of its adolescent study to the U.S.
Food and Drug Administration and other regulators for emergency use authorization in early June.U.S. regulators took about a month to review a similar study from Pfizer/BioNtech, which was authorized for ages 12-15 on May 10.